COVID-19 Impact on Multiple Sclerosis Drugs Market, Global Research Reports 2020-2021
Table of Contents1.1 Research Scope
1.2 Market Segmentation
1.3 Research Objectives
1.4 Research Methodology
1.4.1 Research Process
1.4.2 Data Triangulation
1.4.3 Research Approach
1.4.4 Base Year
1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.5.2 Covid-19 Impact: Commodity Prices Indices
1.5.3 Covid-19 Impact: Global Major Government Policy
1.6 The Covid-19 Impact on Multiple Sclerosis Drugs Industry
1.7 COVID-19 Impact: Multiple Sclerosis Drugs Market Trends
2 Global Multiple Sclerosis Drugs Quarterly Market Size Analysis
2.1 Multiple Sclerosis Drugs Business Impact Assessment - COVID-19
2.1.1 Global Multiple Sclerosis Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
2.1.2 Global Multiple Sclerosis Drugs Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
2.2 Global Multiple Sclerosis Drugs Quarterly Market Size 2020-2021
2.3 COVID-19-Driven Market Dynamics and Factor Analysis
2.3.1 Drivers
2.3.2 Restraints
2.3.3 Opportunities
2.3.4 Challenges
3 Quarterly Competitive Assessment, 2020
3.1 Global Multiple Sclerosis Drugs Quarterly Market Size by Manufacturers, 2019 VS 2020
3.2 Global Multiple Sclerosis Drugs Factory Price by Manufacturers
3.3 Location of Key Manufacturers Multiple Sclerosis Drugs Manufacturing Factories and Area Served
3.4 Date of Key Manufacturers Enter into Multiple Sclerosis Drugs Market
3.5 Key Manufacturers Multiple Sclerosis Drugs Product Offered
3.6 Mergers & Acquisitions, Expansion Plans
4 Impact of Covid-19 on Multiple Sclerosis Drugs Segments, By Type
4.1 Introduction
1.4.1 Injectable medications
1.4.2 Oral medications
1.4.3 Infused medications
4.2 By Type, Global Multiple Sclerosis Drugs Market Size, 2019-2021
4.2.1 By Type, Global Multiple Sclerosis Drugs Market Size by Type, 2020-2021
4.2.2 By Type, Global Multiple Sclerosis Drugs Price, 2020-2021
5 Impact of Covid-19 on Multiple Sclerosis Drugs Segments, By Application
5.1 Overview
5.5.1 Relapsing forms of MS
5.5.2 Improve walking in patients with MS
5.2 By Application, Global Multiple Sclerosis Drugs Market Size, 2019-2021
5.2.1 By Application, Global Multiple Sclerosis Drugs Market Size by Application, 2019-2021
5.2.2 By Application, Global Multiple Sclerosis Drugs Price, 2020-2021
6 Geographic Analysis
6.1 Introduction
6.2 North America
6.2.1 Macroeconomic Indicators of US
6.2.2 US
6.2.3 Canada
6.3 Europe
6.3.1 Macroeconomic Indicators of Europe
6.3.2 Germany
6.3.3 France
6.3.4 UK
6.3.5 Italy
6.4 Asia-Pacific
6.4.1 Macroeconomic Indicators of Asia-Pacific
6.4.2 China
6.4.3 Japan
6.4.4 South Korea
6.4.5 India
6.4.6 ASEAN
6.5 Rest of World
6.5.1 Latin America
6.5.2 Middle East and Africa
7 Company Profiles
7.1 Biogen
7.1.1 Biogen Business Overview
7.1.2 Biogen Multiple Sclerosis Drugs Quarterly Production and Revenue, 2020
7.1.3 Biogen Multiple Sclerosis Drugs Product Introduction
7.1.4 Biogen Response to COVID-19 and Related Developments
7.2 Sanofi
7.2.1 Sanofi Business Overview
7.2.2 Sanofi Multiple Sclerosis Drugs Quarterly Production and Revenue, 2020
7.2.3 Sanofi Multiple Sclerosis Drugs Product Introduction
7.2.4 Sanofi Response to COVID-19 and Related Developments
7.3 Novartis
7.3.1 Novartis Business Overview
7.3.2 Novartis Multiple Sclerosis Drugs Quarterly Production and Revenue, 2020
7.3.3 Novartis Multiple Sclerosis Drugs Product Introduction
7.3.4 Novartis Response to COVID-19 and Related Developments
7.4 Teva
7.4.1 Teva Business Overview
7.4.2 Teva Multiple Sclerosis Drugs Quarterly Production and Revenue, 2020
7.4.3 Teva Multiple Sclerosis Drugs Product Introduction
7.4.4 Teva Response to COVID-19 and Related Developments
7.5 Merck KGaA
7.5.1 Merck KGaA Business Overview
7.5.2 Merck KGaA Multiple Sclerosis Drugs Quarterly Production and Revenue, 2020
7.5.3 Merck KGaA Multiple Sclerosis Drugs Product Introduction
7.5.4 Merck KGaA Response to COVID-19 and Related Developments
7.6 Bayer
7.6.1 Bayer Business Overview
7.6.2 Bayer Multiple Sclerosis Drugs Quarterly Production and Revenue, 2020
7.6.3 Bayer Multiple Sclerosis Drugs Product Introduction
7.6.4 Bayer Response to COVID-19 and Related Developments
7.7 ACORDA
7.7.1 ACORDA Business Overview
7.7.2 ACORDA Multiple Sclerosis Drugs Quarterly Production and Revenue, 2020
7.7.3 ACORDA Multiple Sclerosis Drugs Product Introduction
7.7.4 ACORDA Response to COVID-19 and Related Developments
7.8 Mallinckrodt
7.8.1 Mallinckrodt Business Overview
7.8.2 Mallinckrodt Multiple Sclerosis Drugs Quarterly Production and Revenue, 2020
7.8.3 Mallinckrodt Multiple Sclerosis Drugs Product Introduction
7.8.4 Mallinckrodt Response to COVID-19 and Related Developments
8 Supply Chain and Sales Channels Analysis
8.1 Multiple Sclerosis Drugs Supply Chain Analysis
8.1.1 Multiple Sclerosis Drugs Supply Chain Analysis
8.1.2 Covid-19 Impact on Multiple Sclerosis Drugs Supply Chain
8.2 Distribution Channels Analysis
8.2.1 Multiple Sclerosis Drugs Distribution Channels
8.2.2 Covid-19 Impact on Multiple Sclerosis Drugs Distribution Channels
8.2.3 Multiple Sclerosis Drugs Distributors
8.3 Multiple Sclerosis Drugs Customers
9 Key Findings
10 Appendix
10.1 About Us
10.2 Disclaimer
List of TablesTable 1. Overview of the World Economic Outlook Projections
Table 2. Summary of World Real per Capita Output (Annual percent change; in international currency at purchasing power parity)
Table 3. European Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 4. Asian and Pacific Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 5. Western Hemisphere Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 6. Middle Eastern and Central Asian Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)
Table 7. Covid-19 Impact: Global Major Government Policy
Table 8. The Covid-19 Impact on Multiple Sclerosis Drugs Assessment
Table 9. COVID-19 Impact: Multiple Sclerosis Drugs Market Trends
Table 10. COVID-19 Impact Global Multiple Sclerosis Drugs Market Size
Table 11. Global Multiple Sclerosis Drugs Market Size Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (K Units)
Table 12. Global Multiple Sclerosis Drugs Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026, (USD/Unit)
Table 13. Global Multiple Sclerosis Drugs Quarterly Market Size, 2020 (US$ Million) & (K Units)
Table 14. Global Multiple Sclerosis Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (US$ Million)
Table 15. Global Multiple Sclerosis Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (K Units)
Table 16. Global Multiple Sclerosis Drugs Market Growth Drivers
Table 17. Global Multiple Sclerosis Drugs Market Restraints
Table 18. Global Multiple Sclerosis Drugs Market Opportunities
Table 19. Global Multiple Sclerosis Drugs Market Challenges
Table 20. Key Manufacturers Multiple Sclerosis Drugs Quarterly Revenue, 2019 VS 2020 (US$ Million)
Table 21. Top Manufacturers, Multiple Sclerosis Drugs Market Size, 2019 (K Units) & (US$ Million)
Table 22. Multiple Sclerosis Drugs Factory Price by Manufacturers 2020 (USD/Unit)
Table 23. Location of Key Manufacturers Multiple Sclerosis Drugs Manufacturing Plants
Table 24. Key Manufacturers Multiple Sclerosis Drugs Market Served
Table 25. Date of Key Manufacturers Enter into Multiple Sclerosis Drugs Market
Table 26. Key Manufacturers Multiple Sclerosis Drugs Product Type
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Multiple Sclerosis Drugs Market Size by Type, 2020, (US$ Million)
Table 29. Global Multiple Sclerosis Drugs Market Size by Type, 2020 (K Units)
Table 30. Global Multiple Sclerosis Drugs Price: by Type, 2020-2021 (USD/Unit)
Table 31. Global Multiple Sclerosis Drugs Market Size by Application: 2020-2021 (US$ Million)
Table 32. Global Multiple Sclerosis Drugs Market Size by Application, 2020-2021 (K Units)
Table 33. Global Multiple Sclerosis Drugs Price: by Application, 2020-2021 (USD/Unit)
Table 34. Global Multiple Sclerosis Drugs Market Size by Region, 2019-2021 (US$ Million)
Table 35. Global Multiple Sclerosis Drugs Market Size by Region, 2019-2021 (K Units)
Table 36. By Country, North America Multiple Sclerosis Drugs Market Size, 2019-2021 (US$ Million)
Table 37. By Country, North America Multiple Sclerosis Drugs Market Size, 2019-2021 (K Units)
Table 38. US Multiple Sclerosis Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 39. Canada Multiple Sclerosis Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 40. Macroeconomic Indicators of Europe (Germany, France, UK and Italy)
Table 41. By Country, Europe Multiple Sclerosis Drugs Market Size, 2019-2021 (US$ Million)
Table 42. By Country, Europe Multiple Sclerosis Drugs Market Size, 2019-2021 (K Units)
Table 43. Germany Multiple Sclerosis Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 44. France Multiple Sclerosis Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 45. UK Multiple Sclerosis Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 46. Italy Multiple Sclerosis Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 47. Macroeconomic Indicators of Asia-Pacific (China, Japan, South Korea, India and ASEAN)
Table 48. By Region, Asia-Pacific Multiple Sclerosis Drugs Market Size, 2019-2021 (US$ Million)
Table 49. By Region, Asia-Pacific Multiple Sclerosis Drugs Market Size, 2019-2021 (K Units)
Table 50. China Multiple Sclerosis Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 51. Japan Multiple Sclerosis Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 52. South Korea Multiple Sclerosis Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 53. India Multiple Sclerosis Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 54. ASEAN Multiple Sclerosis Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 55. Latin America Multiple Sclerosis Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 56. Middle East and Africa Multiple Sclerosis Drugs Market Size, 2019-2021 (US$ Million) & (K Units)
Table 57. Biogen Business Overview
Table 58. Biogen Multiple Sclerosis Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 59. Biogen Multiple Sclerosis Drugs Product
Table 60. Biogen Response to COVID-19 and Related Developments
Table 61. Sanofi Business Overview
Table 62. Sanofi Multiple Sclerosis Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 63. Sanofi Multiple Sclerosis Drugs Product
Table 64. Sanofi Response to COVID-19 and Related Developments
Table 65. Novartis Business Overview
Table 66. Novartis Multiple Sclerosis Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 67. Novartis Multiple Sclerosis Drugs Product
Table 68. Novartis Response to COVID-19 and Related Developments
Table 69. Teva Business Overview
Table 70. Teva Multiple Sclerosis Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 71. Teva Multiple Sclerosis Drugs Product
Table 72. Teva Response to COVID-19 and Related Developments
Table 73. Merck KGaA Business Overview
Table 74. Merck KGaA Multiple Sclerosis Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 75. Merck KGaA Multiple Sclerosis Drugs Product
Table 76. Merck KGaA Response to COVID-19 and Related Developments
Table 77. Bayer Business Overview
Table 78. Bayer Multiple Sclerosis Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 79. Bayer Multiple Sclerosis Drugs Product
Table 80. Bayer Response to COVID-19 and Related Developments
Table 81. ACORDA Business Overview
Table 82. ACORDA Multiple Sclerosis Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 83. ACORDA Multiple Sclerosis Drugs Product
Table 84. ACORDA Response to COVID-19 and Related Developments
Table 85. Mallinckrodt Business Overview
Table 86. Mallinckrodt Multiple Sclerosis Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020
Table 87. Mallinckrodt Multiple Sclerosis Drugs Product
Table 88. Mallinckrodt Response to COVID-19 and Related Developments
Table 89. Multiple Sclerosis Drugs Distributors List
Table 90. Multiple Sclerosis Drugs Customers List
Table 91. Covid-19 Impact on Multiple Sclerosis Drugs Customers
List of FiguresFigure 1. Multiple Sclerosis Drugs Product Picture
Figure 2. Multiple Sclerosis Drugs Market Segmentation
Figure 3. Research Objectives
Figure 4. Research Process
Figure 5. Data Triangulation
Figure 6. Research Approach
Figure 7. Commodity Prices-Metals Price Indices
Figure 8. Commodity Prices- Precious Metal Price Indices
Figure 9. Commodity Prices- Agricultural Raw Material Price Indices
Figure 10. Commodity Prices- Food and Beverage Price Indices
Figure 11. Commodity Prices- Fertilizer Price Indices
Figure 12. Commodity Prices- Energy Price Indices
Figure 13. G20+: Economic Policy Responses to COVID-19
Figure 14. Global Multiple Sclerosis Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (US$ Million)
Figure 15. Global Multiple Sclerosis Drugs Market Size, Pre-COVID-19 and Post- COVID-19, Year-over-Year Growth Rate, 2015-2026 (%)
Figure 16. Global Multiple Sclerosis Drugs Market Size, Quarterly Growth, 2020-2021 (%)
Figure 17. Global Multiple Sclerosis Drugs Market Size, Market Share by Type, 2019 VS 2020 (%)
Figure 18. Global Multiple Sclerosis Drugs Market Size, Market Share by Application, 2019 VS 2020 (%)
Figure 19. Global Multiple Sclerosis Drugs Market Size Market Share by Region, 2019 VS 2020 (%)
Figure 20. United States Composite PMI and GDP
Figure 21. Eurozone Composite PMI and GDP
Figure 22. Eurozone Core v. Periphery PMI Output Indices
Figure 23. Core v. Periphery PMI Employment Indices
Figure 24. UK Composite PMI and GDP
Figure 25. Caixin China Composite Output Index
Figure 26. Caixin China General Services Business Activity Index
Figure 27. Japan Composite Output Index
Figure 28. South Korea Manufacturing PMI
Figure 29. India Composite Output Index
Figure 30. ASEAN Manufacturing PMI
Figure 31. By Region, Asia-Pacific Multiple Sclerosis Drugs Market Size Market Share, 2019-2021